HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kielstein, J. T. Articles by Cooke, J. P. Search for Related Content PubMed PubMed Citation Articles by Kielstein, J. T. Articles by Cooke, J. P. Related Collections Endocrinology and Metabolism

Should We Measure Asymmetric Dimethylarginine in Patients with Coronary Artery Disease?

Division of Cardiovascular Medicine, Stanford University Medical Center, Stanford, CA

^aAddress correspondence to this author at: Division of Cardiovascular Medicine, Stanford University School of Medicine, 300 Pasteur Drive, Stanford, CA 94035 U S A. Fax 650-725-1599; e-mail john.cooke@stanford.edu.

The first 20% of the full text of this article appears below.

In this issue of Clinical Chemistry, Meinitzer et al. (1) present data from The Ludwigshafen Risk and Cardiovascular Health Study in which they assess asymmetric dimethylarginine (ADMA) as a cardiovascular biomarker in 3238 patients. Coronary angiography identified 2543 patients with coronary artery disease as well as 695 persons without significant disease. Study participants were followed for more than 5 years. The major finding of the study was that plasma ADMA was an independent predictor of total and cardiovascular mortality.

What Is ADMA?

ADMA is a naturally occurring amino acid that has the interesting property of competitively inhibiting the activity of nitric oxide synthase (NOS). ADMA is produced by methylation of arginine residues in intracellular proteins via protein arginine N-methyltransferases (PRMT). When these proteins are hydrolyzed, ADMA is released. ADMA is excreted in the urine, and, not surprisingly, plasma ADMA is increased in patients with end-stage renal disease (2). Parenthetically, patients with renal disease have an increased risk of cardiovascular morbidity and mortality, and in these patients plasma ADMA concentrations carry prognostic information (3). The primary route of ADMA clearance, however, is by enzymatic degradation (Fig. 1 ). Dimethylamine dimethylaminohydrolase (DDAH) converts ADMA to citrulline and dimethylamine. By regulating plasma and tissue concentrations of ADMA, DDAH protects NOS activity. Compelling evidence for the critical role of DDAH as an NOS regulator was demonstrated by studies of the transgenic DDAH mouse. These animals manifest increased DDAH activity, decreased plasma ADMA concentrations, increased plasma and urinary nitrogen . . . [Full Text of this Article]

Why Is ADMA important?

Can We Lower ADMA Concentrations?

Should We Measure ADMA in Every Patient with Coronary Artery Disease?

The following articles in journals at HighWire Press have cited this article:

				E. Jahangir, J. A Vita, D. Handy, M. Holbrook, J. Palmisano, R. Beal, J. Loscalzo, and R. T Eberhardt The effect of l-arginine and creatine on vascular function and homocysteine metabolism Vascular Medicine, August 1, 2009; 14(3): 239 - 248. [Abstract] [PDF]